Relmada Therapeutics Advances NDV-01 Toward IND Filing with $217M Cash Runway
Event summary
- Relmada Therapeutics expects to file IND for NDV-01 by year-end 2026, with Phase 3 RESCUE program initiation upon clearance.
- Sepranolone IND filing also anticipated by year-end 2026, targeting Prader-Willi Syndrome in Phase 2 study.
- Company added to Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
- Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029.
The big picture
Relmada Therapeutics is entering a critical execution phase with two key programs advancing toward registrational development. The company's strong cash position provides runway through 2029, but success hinges on timely IND filings and smooth trial initiations in competitive therapeutic areas. The addition to Russell indexes may enhance visibility among institutional investors.
What we're watching
- Regulatory Alignment
- Whether FDA alignment on NDV-01 and sepranolone pathways will hold through IND filings.
- Execution Risk
- The pace at which manufacturing and CMC activities for both programs can be completed without delays.
- Market Positioning
- How Relmada’s inclusion in Russell indexes will impact investor perception and liquidity.
Related topics